Clinical Trial Update: A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis [Phase 3]

View source ↗

Summary

Long-term safety extension study of THC/CBD in multiple sclerosis has completed Phase 3 with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Multiple Sclerosis, Spasticity | Phase 3 | Status: COMPLETED | Results posted: 2012-08-17